唑吡坦对不稳定型心绞痛伴自述失眠患者的临床疗效  

Clinical efficacy of zolpidemin on patients with unstable angina pectoris and self-reported insomnia

作　　者：赵红亮[1] 李柳[1] 贾玮玲 魏立业[1] 夏岳[1] 戚国庆[1] ZHAO Hong-liang;LI Liu;JIA Wei-ling;WEI Li-ye;XIA Yue;QI Guo-qing(Department of Cardiology,the First Hospital of Hebei Medical University,Shijiazhuang HEBEI 050031,China)

机构地区：[1]河北医科大学第一医院心内科

出　　处：《中国新药与临床杂志》2019年第12期730-734,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：河北省科技厅基金项目（182777229）;河北省卫健委基金项目（20190449

摘　　要：目的观察唑吡坦对不稳定型心绞痛(UAP)伴自述失眠患者的临床疗效。方法选取UAP伴自述失眠患者180例,随机分为对照组和治疗组各90例。在治疗UAP基础用药同时治疗组加用唑吡坦5 mg·d^-1睡前口服,对照组则给予安慰剂,2组患者疗程均为4周。运用匹兹堡睡眠质量指数(PSQI)及国际统一睡眠效率公式评估患者睡眠情况,比较2组UAP治疗效果,观察不良反应发生情况。结果治疗后,治疗组患者PSQI各因子及总评分均较治疗前显著下降,且显著低于对照组(P<0.05)。治疗组和对照组失眠改善总有效率分别为94%和68%,UAP治疗总有效率分别为92%和79%,治疗组显著优于对照组(P<0.05)。治疗组肌钙蛋白I和D-二聚体水平显著低于对照组(P<0.05)。2组均无严重不良反应发生。结论唑吡坦治疗UAP伴自述失眠患者疗效显著,可明显改善患者睡眠质量和UAP临床疗效,且安全性较高,值得临床推广应用。AIM To observe the clinical efficacy of zolpidem in patients with unstable angina pectoris(UAP)and self-reported insomnia.METHODS One hundred and eighty patients with UAP and self-reported insomnia were randomly divided into control group and treatment group(n=90 for each).The basic drug treatment for UAP was given in both groups.At the same time,zolpidem 5 mg·d^-1 was taken orally in the treatment group,while placebo was given in the control group before bedtime.Both groups were treated for 4 weeks.The Pittsburgh sleep quality index(PSQI)and the international uniform sleep efficiency formula were used to evaluate the sleep quality of patients.The therapeutic effects of UAP between the two groups were compared before and after the treatment,and adverse reactions were observed.RESULTS After the treatment,all factors and total scores of PSQI in the treatment group were significantly lower than that before treatment,and significantly lower than that in the control group(P<0.05).The improved rate of insomnia was 94%and 68%,and the total effective rate of UAP was 92%and 79%in the treatment group and the control group respectively.The treatment group was significantly better than the control group(P<0.05).Cardiac troponin I and D-dimer levels in the treatment group were significantly lower than those in the control group(P<0.05).And there were no serious adverse reactions in both groups(P<0.05).CONCLUSION Zolpidem is effective in the treatment of patients with UAP and self-reported insomnia.It can significantly improve sleep quality and clinical efficacy,which is safety and worthy of clinical promotion.

关 键 词：唑吡坦 心绞痛 不稳定型 失眠 自述 治疗结果 

分 类 号：R541.4[医药卫生—心血管疾病] R971.3[医药卫生—内科学]